Seeking Alpha

NPS Pharmaceuticals CEO (NPSP -2.9%) Francois Nader tells Minyanville that its drug aimed at...

NPS Pharmaceuticals CEO (NPSP -2.9%) Francois Nader tells Minyanville that its drug aimed at treating hypoparathyroidism will be successful following positive clinical testing of the treatment, helping offset problems with its experimental Gattex drug. Stifel Nicolaus expects both drugs to eventually win US approval, setting a price target of $11 on shares. Leerink Swann aims even higher with a $14-$16 price target - repping a tripling of the stock's current value.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs